About Debiopharm
Debiopharm is a Healthcare company based in Lausanne (Switzerland) founded in 1979. Debiopharm has completed 1 acquisition, including Affinium Pharmaceuticals. Its website debiopharm.com draws about 15 thousand monthly visits. Debiopharm offers products and services including Drug Development Services, Manufacturing Services, and Innovation Fund. Its focus areas include Diversified Pharmaceuticals and Drugs. Its legal entity is Debiopharm International. Its competitors include Merck, Roivant Sciences, AbbVie, Gilead and Lilly and 5 more; 1 of its 10 listed competitors has raised funding.
Company details
Biopharmaceutical company focused on oncology, infectious diseases, and orphan drugs. The lead drug candidates are Xevinapant for cancer, Afabicin for orthopedics, Alisporivir for cOVID and GI disorders, Debio 1450, ABSSSI, for staph infections.
- Headquarters Lausanne, Switzerland
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website debiopharm.com
- Social LinkedIn X Facebook YouTube
- Legal Name Debiopharm International
- Investors
- Investments & Acquisitions
Products & Services of Debiopharm
Debiopharm offers a comprehensive portfolio of products and services, including Drug Development Services, Manufacturing Services, and Innovation Fund.
Develops compounds for oncology and infections through partnerships.
Produces drugs for development and commercialization processes.
Invests in digital health and smart data start-ups globally.
Apps and channels of Debiopharm
its YouTube channel DebiopharmTV has 377 subscribers and 30 videos.
Videos from Debiopharm
The most watched videos on Debiopharm's YouTube channel, DebiopharmTV (377 subscribers). Click a video to play it here.
More on DebiopharmTV.
Funding Insights of Debiopharm
- Total Rounds 2
- First Round $2.1M
(May 2019)
- Investors Count 1
All 2 funding rounds of Debiopharm with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
1 investors in total: 1 institutional.
Investors in Debiopharm
Debiopharm has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include CARB-X.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Antibiotics, vaccines, and diagnostics against drug-resistant bacteria are developed. | 2016 | carb-x.org | Boston, United States |
Investor details for Debiopharm
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Debiopharm
Debiopharm has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Affinium Pharmaceuticals.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Canadian, clinical stage biopharma developing bacterial FAS II-inhibitors, highly specific to Staphylococcus sp. Acquired by Debiopharm | afnm.com | Toronto, Canada | 2000 | Feb 2014 | •••• |
Complete acquisition details for Debiopharm
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Debiopharm
4 dated milestones of Debiopharm across 42 years, from founding to its latest funding, stage changes and deals.
- Founded Debiopharm is founded.
- Acquisition Acquires Affinium Pharmaceuticals.
- Funding First funding round of $2.1M.
- Funding Latest funding round, Grant,.
Competitors of Debiopharm
Debiopharm has 10 listed competitors in our database, 1 of them funded. They include Merck, Roivant Sciences, AbbVie, Gilead and Lilly, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| merck.com | 1891 | Kenilworth, United Kingdom | – | 781 | Pharmaceutical products are manufactured and marketed worldwide. | |
| roivant.com | 2014 | New York, United States | $1.3B | 662 | Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | |
| abbvie.com | 2012 | Chicago, United States | – | 8,667 | Biopharmaceutical research and drug development are conducted globally by AbbVie. | |
| gilead.com | 1987 | Foster, United States | – | 4,267 | Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | |
| lilly.com | 1876 | United States | – | 39,000 | Traditional pharmaceutical medicines are developed for multiple health fields. | |
| vrtx.com | 1989 | United States | – | 5,400 | Developer of drugs for the treatment of multiple disorders | |
| unither.com | 1998 | Silver Spring, United States | – | 1,168 | Treatments for chronic and life-threatening diseases are developed and commercialized. | |
| morphosys.com | 1992 | Planegg, Germany | – | 732 | Therapeutic antibodies for cancer and other diseases are developed. | |
| roche.com | 1896 | Basel, Switzerland | – | 2,382 | Pharmaceuticals and diagnostics kits are developed for various diseases. | |
| eisai.com | 1941 | Tokyo, Japan | – | 10,419 | Drugs for oncology and neurological disorders are developed by Eisai. |
Detailed competitors of Debiopharm
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Debiopharm
The website of Debiopharm (debiopharm.com) receives about 15.1K visits a month and ranks #1,818,608 among all websites worldwide, #2,483 in Biotechnology and Pharmaceuticals.
- Monthly visits15.1K
▲ 14.7% vs previous month
- Unique visitors5.8K
per month
- Global rank#1,818,608
among all websites
- Category rank#2,483
Health · Biotechnology and Pharmaceuticals
- Bounce rate41%
- Pages per visit1.8
- Average visit21 sec
- DevicesDesktop 42% · Mobile 58%
Websites whose visitors overlap most with Debiopharm. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
marinabio.com | marinabio.com | 100% | – | – | – |
| cambrex.com | 77% | 35K | #883,665 | View details | |
| medicinova.com | 75% | 3.5K | #5,782,921 | View details | |
vaud-pharmacies.ch | vaud-pharmacies.ch | 58% | – | – | – |
sanofi-aventis.com | sanofi-aventis.com | 55% | – | #13,083,503 | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for Debiopharm
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Pharmaceuticals & Distribution
10 companies that operate in the same segment as Debiopharm (Pharmaceuticals & Distribution), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | Kenilworth, Warwickshire, United Kingdom | – | USD 64.93 B | 781 | |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | – | USD 33.23 B | 28,000 | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | – | USD 61.16 B | 55,000 | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | – | USD 65.18 B | 47,000 | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | Foster City, California, United States | – | USD 29.45 B | 17,600 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 213.52 M | USD 29.62 M | 225 | |
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | Libertyville, Illinois, United States | – | USD 44.33 B | 3,710 | |
Medicines and health products are retailed through pharmacy outlets. | 2006 | Hyderabad, Telangana, India | USD 268.78 M | USD 734.57 M | 25,010 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Debiopharm
Complete news archive for Debiopharm
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Debiopharm
Debiopharm was founded in 1979 and raised its 1st funding round 40 years after it was founded.
Debiopharm is headquartered in Lausanne, Switzerland. It is registered at Lausanne, Vaud, Switzerland.
Biopharmaceutical company focused on oncology, infectious diseases, and orphan drugs. The lead drug candidates are Xevinapant for cancer, Afabicin for orthopedics, Alisporivir for cOVID and GI disorders, Debio 1450, ABSSSI, for staph infections.
Debiopharm's top competitors include Merck, Roivant Sciences and AbbVie.
Debiopharm offers Drug Development Services, Manufacturing Services, and Innovation Fund.
Debiopharm has made 1 acquisition, including Affinium Pharmaceuticals.
Debiopharm has 1 investor. Key investors include CARB-X.
Debiopharm operates through Debiopharm International.